ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2022
Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 7 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Exposome Risk Factors for Vitiligo: A Systematic Evidence Review.American journal of clinical dermatology · 2026Pooled it
- Cross-Cultural Beliefs and Stigmatization in Vitiligo: A Systematic Review.Journal of cosmetic dermatology · 2026Pooled it
- The Effectiveness of Home-Based Phototherapy in Vitiligo: A Systematic Review and Meta-Analysis.Photodermatology, photoimmunology & photomedicine · 2026Pooled it
- Systematic evidence grading evaluates multisystemic associations and risks of vitiligo.Nature communications · 2025Pooled it
- Global prevalence of sexual dysfunction in women with skin diseases: a systematic review and meta-analysis.BMC women's health · 2025Pooled it
- Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Global clinicoepidemiological pattern of childhood vitiligo: a systematic review and meta-analysis.BMJ paediatrics open · 2023Pooled it
- Objective Assessment of Target Vitiligo Areas by Semiautomatic Analysis of Standardized UV Images.JAMA dermatology · 2025Trial
- [Vitiligo in Germany : A claims data analysis on prevalence, comorbidity, and treatment patterns].Dermatologie (Heidelberg, Germany) · 2026Article
- Exploring and Comparing the Psychosocial Impacts of Vitiligo on a Broader Scale: An International Survey via the Use of Social Media.The Australasian journal of dermatology · 2026Article
- Prevalence and Clinical Characteristics of Vitiligo-Associated Hearing Loss Among Patients in a Phase 2 Clinical Trial of Povorcitinib.Dermatology and therapy · 2026Article
- Management of Facial Immune Checkpoint Inhibitor-Induced Vitiligo with Topical Ruxolitinib: Quantitative Assessment Using a Semi-Automatic Tool.Current oncology (Toronto, Ont.) · 2026Article
- Quality of life impairment in vitiligo: A comprehensive review of psychosocial and clinical determinants.The Journal of international medical research · 2026Review
- Validation of Self-Reported Vitiligo Prevalence among Adults in the USA and Europe Using the 2024 National Health and Wellness Survey.Dermatology and therapy · 2026Article
- Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update.Inflammatory bowel diseases · 2026Review
- Health-Related Quality of Life and Psychological Burden of Patients With Vitiligo in Japan.The Journal of dermatology · 2026Article
- Well-being in German patients with vitiligo in genital and visible areas - a pilot study.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Understanding vitiligo-related concerns through online discourse: an AI-assisted cross-platform study of Chinese and global communities.Frontiers in public health · 2026Article
- Correlation of disease activity in vitiligo patients and its relation with HSP70 expression.Bioinformation · 2026Article
- Retinal Vulnerability to Light Pollution in Vitiligo: A Narrative Review of the Role of Melanin Loss in Ocular Phototoxicity.Dermatology (Basel, Switzerland) · 2026Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundVitiligo, an autoimmune disorder characterised by skin depigmentation, is associated with reduced quality of life (QoL). Vitiligo may be under-reported, in part because of misconceptions that it is a cosmetic disease.
objectivesThis survey sought to characterise vitiligo prevalence and explore the relationship between sociodemographic and clinical characteristics with QoL in a population-based, multinational study.
methodsParticipants aged ≥18 years were recruited via an online panel in Europe, Japan and the USA to answer questions regarding skin disorders they may have experienced. Those reporting vitiligo (diagnosed or undiagnosed) or vitiligo signs (experiencing loss of skin colour but unaware of vitiligo and not diagnosed) were included in the analyses of vitiligo prevalence. Participants who self-reported physician-diagnosed vitiligo were given a broader survey to characterise disease progression, management and QoL (as measured with the Vitiligo-specific QoL [VitiQoL] instrument).
resultsThe total estimated vitiligo prevalence among 35 694 survey participants (Europe, n = 18 785; USA, n = 8517; Japan, n = 8392) was 1.3% (diagnosed, 0.6%; undiagnosed, 0.4%; vitiligo signs, 0.3%). Among 219 patients formally diagnosed with vitiligo (Europe, n = 150; USA, n = 48; Japan, n = 21), total VitiQoL scores were associated with age (P = 0.00017), disease extent (P < 0.0001), disease progression (P < 0.0001), disease management (P < 0.0001) and time since diagnosis (P = 0.0015). Behaviour scores varied based on skin phototype (P = 0.024) and ethnicity (P = 0.048). Higher total VitiQoL scores were reported in patients with head lesions (P = 0.027) and those with head and hand and/or wrist lesions (P = 0.018). Substantial high concern (rated 8-10 on an 11-point Likert scale) for lesions was found across all body areas and varied with geographical region.
conclusionsThe vitiligo prevalence rate may be higher than previously reported, with a substantial proportion attributed to people who have not received a formal diagnosis. Among formally diagnosed patients with vitiligo, QoL was most severely impacted by more progressive and higher extent of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.